Alectinib Pharmacokinetic in Patients With NSCLC

Instituto Nacional de Cancerologia de Mexico

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Non-small Cell Lung Cancer Stage IIIB

ALK Gene Mutation

Treatments

Drug: Alectinib Oral Product

Study type

Interventional

Funder types

Other

Identifiers

NCT05713006

022/023/ICI_CEI/1583/21_V.2

Details and patient eligibility

About

This interventional study aims to determine the pharmacokinetics of orally administered alectinib with dose escalation from 300 mg to 600 mg twice daily in Mexican patients with advanced ALK-positive NSCLC.

The main question it aims to answer is: what will be the peak plasma concentrations of alectinib following sequential dose escalation (300, 450, and 600 mg BID) over nine weeks of pharmacokinetic evaluation (phase I) in Mexican patients with advanced ALK-rearranged NSCLC?

In phase I (on days 0, 21, and 42), oral alectinib will be administered twice per day (BID) to patients with ALK-positive NSCLC; starting with 300 mg BID in 21-day cycles and dose escalation in 150 mg increments until 600 mg BID. Blood samples will be taken before and after administration of each dose (on days 1, 22, and 43). The primary endopoints in phase I will be dose-limiting toxicity (DLT) and PK parameters (Cmax. maximum plasma concentration; Tmax: time to reach maximum concentration: AUC 1-12: area under plasma ocncentrations-time curve steady-state concentration). At the end of the last blood collection (at day 43), the evaluation of each cycle will be at 600 mg, and the participant will be discharged to continue their treatment on an outpatient basis. Phase one will finish on day 63 of the study.

In phase II, the chosen BID dose based on the phase I portion will be administrated until disease progression, development of unacceptable side effects, or withdrawal of consent. The primary endpoint in phase 2 is the overall response rate (ORR) per RECIST V.1.1.

Full description

Alectinib will be administrated under fast conditions.

The primary endpoint of the phase II part was ORR. Other secondary endpoints in phase II are progression-free survival (PFS), overall survival (OS), intracranial response (ICR), and duration of response (DOR).

Exploratory endpoints in this follow-up analysis included the evaluation of the correlation between tumor shrinkage and PFS and chosen dose to relieve cancer symptoms.

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Both sexes
≥ 18 years old
Pathologically confirmed diagnosis of NSCLC
Stage IIIB - IV by the American Joint Committee of Cancer Version 8.
Recurrent disease (at least 180 days from curative intent treatment)
ALK rearrangements tested by FDA-approved tests (IHQ or FISH)
Karnofsky PS scale ≥ 70%
Having received first-line treatment with anti-ALK inhibitors and one previous line of platinum-based chemotherapy.
Measurable disease as referred by RECIST version 1.1
Symptomatic brain metastases could receive prior treatment with radiotherapy or surgery for at least two weeks before treatment initiation.
Asymptomatic brain metastases could not receive local therapy before study inclusion.
Negative highly sensitive pregnancy test (serum or urine) within 72 days before first dose intervention.
Sexually active patients should use a contraceptive method with a failure rate of less than 1% per year.
Signed written informed consent
Adequate organ function (hematological, liver, and renal function)
Life expectancy of at least 12 weeks

Exclusion criteria

Carcinomatous meningitis confirmed by a positive CRL cytology or highly suspicious brain MRI.
Previous malignancies except for any carcinoma in-situ
Treatment with other anti-cancer therapy
Participating in other clinical trials in the former four weeks
Any other serious condition or uncontrolled active infection, altered mental status, or psychiatric condition that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.
Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.
Active HIV infection.
Breastfeeding.